Cargando…

The association of pretreatment low skeletal muscle mass with chemotherapy dose‐limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high‐dose cisplatin

BACKGROUND: Low skeletal muscle mass (SMM) is an adverse prognostic factor for chemotherapy dose‐limiting toxicity (CDLT). In patients with locally advanced head and neck squamous cell carcinoma (HNSCC) undergoing chemoradiotherapy (CRT), low SMM is a predictor for CDLT. We aimed to validate these f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bril, Sandra I., Al‐Mamgani, Abrahim, Chargi, Najiba, Remeijer, Peter, Devriese, Lot A., de Boer, Jan Paul, de Bree, Remco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298001/ https://www.ncbi.nlm.nih.gov/pubmed/34713519 http://dx.doi.org/10.1002/hed.26919

Ejemplares similares

Patterns, Predictors, and Prognostic Value of Skeletal Muscle Mass Loss in Patients with Locally Advanced Head and Neck Cancer Undergoing Cisplatin-Based Chemoradiotherapy
por: Chargi, Najiba, et al.
Publicado: (2021)

Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol
por: Schaeffers, Anouk W. M. A., et al.
Publicado: (2023)

The Predictive Value of Low Skeletal Muscle Mass Assessed on Cross-Sectional Imaging for Anti-Cancer Drug Toxicity: A Systematic Review and Meta-Analysis
por: Huiskamp, Laura F. J., et al.
Publicado: (2020)

The predictive and prognostic value of low skeletal muscle mass for dose-limiting toxicity and survival in head and neck cancer patients receiving concomitant cetuximab and radiotherapy
por: Huiskamp, L. F. J., et al.
Publicado: (2020)

Association of low skeletal muscle mass and systemic inflammation with surgical complications and survival after microvascular flap reconstruction in patients with head and neck cancer
por: Chargi, Najiba, et al.
Publicado: (2022)

Low skeletal muscle mass is predictive of dose-limiting toxicities in head and neck cancer patients undergoing low-dose weekly cisplatin chemoradiotherapy
por: Becker, Jan-Niklas, et al.
Publicado: (2023)

Sarcopenia is a prognostic factor for overall survival in elderly patients with head-and-neck cancer
por: Chargi, N., et al.
Publicado: (2019)

Arterial calcification on preoperative computed tomography imaging as a risk factor for pharyngocutaneous fistula formation after total laryngectomy
por: Bril, Sandra I., et al.
Publicado: (2021)

The association between skeletal muscle measures and chemotherapy‐induced toxicity in non‐small cell lung cancer patients
por: de Jong, Corine, et al.
Publicado: (2022)

Protocolised way to cope with anatomical changes in head & neck cancer during the course of radiotherapy
por: van Beek, Suzanne, et al.
Publicado: (2019)

Nephrotoxicity as a Dose-Limiting Factor in a High-Dose Cisplatin-Based Chemoradiotherapy Regimen for Head and Neck Carcinomas
por: Hoek, Jantien, et al.
Publicado: (2016)

Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer
por: Szturz, Petr, et al.
Publicado: (2019)

Low skeletal muscle mass predicts frailty in elderly head and neck cancer patients
por: Meerkerk, C. D. A., et al.
Publicado: (2021)

Concurrent Chemoradiotherapy With Weekly Low-Dose Cisplatin for Japanese Patients With Head and Neck Squamous Cell Carcinoma
por: Shinohara, Shogo, et al.
Publicado: (2021)

Deterioration of Intended Target Volume Radiation Dose Due to Anatomical Changes in Patients with Head-and-Neck Cancer
por: Hamming-Vrieze, Olga, et al.
Publicado: (2021)

Nutritional interventions in patients with head and neck cancer undergoing chemoradiotherapy: Current practice at the Dutch Head and Neck Oncology centres
por: Kok, Annemieke, et al.
Publicado: (2021)

Adaptive FDG-PET/CT guided dose escalation in head and neck squamous cell carcinoma: Late toxicity and oncologic outcomes (The ADMIRE study)
por: Al-Mamgani, Abrahim, et al.
Publicado: (2023)

Pretreatment screening for distant metastases in the Dutch head and neck centers: 10 years later
por: Senft, Asaf, et al.
Publicado: (2016)

Incidence of contralateral regional failure in the electively irradiated contralateral neck of patients with head and neck squamous cell carcinoma
por: de Veij Mestdagh, Pieter D., et al.
Publicado: (2019)

Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers
por: Shimada, Rie, et al.
Publicado: (2018)

Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low‐dose fraction radiation
por: Zhao, Lili, et al.
Publicado: (2019)

Effects of Pretreatment With Single-Dose or Intermittent Oxygen on Cisplatin-Induced Nephrotoxicity in Rats
por: Rasoulian, Bahram, et al.
Publicado: (2014)

Preoperative low skeletal muscle mass as a risk factor for pharyngocutaneous fistula and decreased overall survival in patients undergoing total laryngectomy
por: Bril, Sandra I., et al.
Publicado: (2019)

Comparison of vinorelbine with cisplatin in concomitant chemoradiotherapy in head and neck carcinoma
por: Devleena,, et al.
Publicado: (2010)

Postoperative chemoradiotherapy in gastric cancer – a phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy
por: Jansen, E P M, et al.
Publicado: (2007)

Diagnostic test accuracy of sentinel lymph node biopsy in squamous cell carcinoma of the oropharynx, larynx, and hypopharynx: A systematic review and meta‐analysis
por: van den Bosch, Sven, et al.
Publicado: (2022)

The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis
por: de Ruiter, Emma J., et al.
Publicado: (2017)

The prognostic role of NK cells and their ligands in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis
por: Bisheshar, Sangeeta K., et al.
Publicado: (2020)

Trismus Occurrence and Link With Radiotherapy Doses in Head and Neck Cancer Patients Treated With Chemoradiotherapy
por: Faravel, Kerstin, et al.
Publicado: (2023)

The Cumulative Cisplatin Dose Affects the Long-Term Survival Outcomes of Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy
por: Peng, Hao, et al.
Publicado: (2016)

First experiences with (177)Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer
por: Klein Nulent, Thomas J. W., et al.
Publicado: (2021)

Interobserver agreement of skeletal muscle mass measurement on head and neck CT imaging at the level of the third cervical vertebra
por: Bril, S. I., et al.
Publicado: (2019)

Feasibility of a supervised and home‐based tailored exercise intervention in head and neck cancer patients during chemoradiotherapy
por: Kok, Annemieke, et al.
Publicado: (2022)

Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer
por: Wolff, Hendrik Andreas, et al.
Publicado: (2008)

Outcomes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer Patients
por: Kim, Jung Sun, et al.
Publicado: (2014)

Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: a multicenter analysis in Thailand
por: Ngamphaiboon, Nuttapong, et al.
Publicado: (2020)

Pretreatment ADC is not a prognostic factor for local recurrences in head and neck squamous cell carcinoma when clinical T-stage is known
por: Peltenburg, Boris, et al.
Publicado: (2019)

Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
por: Cho, Hundo, et al.
Publicado: (2022)

Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
por: Cho, Hundo, et al.
Publicado: (2022)

Dual time point imaging in locally advanced head and neck cancer to assess residual nodal disease after chemoradiotherapy
por: Soffers, Frederik, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kii9lha191otbkasjmhat47l4a